NCT05361395

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 184 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Conditions

• Extensive Stage Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Tarlatamab	Tarlatamab will be administered as an intravenous (IV) infusion.
DRUG	Carboplatin	Carboplatin will be administered as an intravenous (IV) infusion.
DRUG	Etoposide	Etoposide will be administered as an intravenous (IV) infusion.
DRUG	Atezolizumab	Atezolizumab will be administered as an intravenous (IV) infusion.
DRUG	Durvalumab	Durvalumab will be administered as an intravenous (IV) infusion.

Timeline

• Start date: 2022-08-24
• Primary completion: 2028-08-28
• Completion: 2028-08-28
• First posted: 2022-05-04
• Last updated: 2026-03-03

Locations

44 sites across 15 countries: United States, Australia, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, South Korea, Spain, Switzerland, Taiwan

Regulatory

• FDA-regulated drug study